Luksa J, Josíc D, Podobnik B, Furlan B, Kremser M
Lek Pharmaceutical and Chemical Company d.d., Ljubljana, Slovenia.
J Chromatogr B Biomed Sci Appl. 1997 Jun 6;693(2):367-75. doi: 10.1016/s0378-4347(97)00069-8.
Pharmacokinetic studies of optically pure compounds after single enantiomer administration are becoming increasingly important. The process of racemization in vivo can diminish all expected advantages of single enantiomer treatment. Amlodipine, one of the calcium channel blockers, currently used in therapy as a racemate, is one of such drugs under study. In order to administer single enantiomers of amlodipine to healthy volunteers both were chromatographically purified and characterised. The two optical isomers of amlodipine, active S-(-)- and non-active R-(+)-amlodipine, were purified using chromatographic procedure adopted from the analytical separation. Enantiomers were successfully converted to benzenesulphonic salt without any racemization. All semi-preparative purifications were monitored with complementary analytical methods, HPLC and CE, along with the determination of optical activity so that the final product was sufficiently defined for further in vivo studies. The analytical method developed for the determination of plasma concentrations of each enantiomer of amlodipine in these studies is also briefly described.
对光学纯化合物进行单一对映体给药后的药代动力学研究正变得越来越重要。体内消旋化过程可能会削弱单一对映体治疗所有预期的优势。氨氯地平作为钙通道阻滞剂之一,目前以消旋体形式用于治疗,是正在研究的此类药物之一。为了给健康志愿者施用氨氯地平的单一对映体,两种对映体均经过色谱纯化和表征。氨氯地平的两种光学异构体,即活性的S-(-)-氨氯地平和无活性的R-(+)-氨氯地平,采用从分析分离中采用的色谱方法进行纯化。对映体成功转化为苯磺酸盐,未发生任何消旋化。所有半制备纯化过程均采用HPLC和CE等互补分析方法进行监测,并测定旋光性,以便最终产物能得到充分鉴定以用于进一步的体内研究。本文还简要描述了在这些研究中开发的用于测定氨氯地平各对映体血浆浓度的分析方法。